Budenofalk Uno 9 mg gastro‑resistant granules
Authors:
M. Lukáš
Authors‘ workplace:
Klinické a výzkumné centrum pro střevní záněty ISCARE I. V. F. a. s. a Ústav lékařské biochemie a laboratorní diagnostiky 1. LF UK a VFN v Praze
Published in:
Gastroent Hepatol 2015; 69(4): 392-393
Category:
Drug Profile
doi:
https://doi.org/10.14735/amgh2015392
Sources
1. Souhrn údajů o přípravku. Budenofalk Uno 9 mg enterosolventní granule, Sp. zn. sukls82708 2014.
2. Dignass A, Stoynoiv S, Dorofeyev AE et al. Once versus three times daily dosing of oral budesonide for active Crohn’s disease: a double‑blind, double‑dummy, randomised trial. J Crohns Colitis 2014; 8(9): 970– 980. doi: 10.1016/ j.crohns. 2014. 01.021.
3. Miehlke S, Madisch A, Kupcinskas L et al. Budesonide is more effective than mesalamine or placebo in short‑term treatment of collagenous colitis. Gastroenterology 2014; 146(5): 1222– 1230. doi: 10.1053/ j.gastro.2014.01.019.
Labels
Paediatric gastroenterology Gastroenterology and hepatology SurgeryArticle was published in
Gastroenterology and Hepatology
2015 Issue 4
Most read in this issue
- Unusual cause of diarrhoea – cholecystocolic fistula: case interpretation and overview of literature
- Budenofalk Uno 9 mg gastro‑resistant granules
- Diagnosis and treatment of anemia in patients with diseases of the gastrointestinal tract
- Middle generation of gastroenterologists and hepatologists